Anzeige
Mehr »
Mittwoch, 03.09.2025 - Börsentäglich über 12.000 News
Geheime Uran-Aktie: Ist das der historische "New Deal"-Moment für amerikanischen Uransektor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B8P4 | ISIN: US7404441047 | Ticker-Symbol: P4L
Tradegate
02.09.25 | 18:09
162,00 Euro
0,00 % 0,00
Branche
Elektrotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PREFORMED LINE PRODUCTS COMPANY Chart 1 Jahr
5-Tage-Chart
PREFORMED LINE PRODUCTS COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
160,00161,0016:42
160,00161,0016:41
ACCESS Newswire
93 Leser
Artikel bewerten:
(0)

OGRD Alliance: PLPC-DB: De-Risked Oncology Immunotherapy Asset With Global Licensing Window and STIP-NAM Framework

ORLANDO, FL / ACCESS Newswire / September 3, 2025 / OGRD Alliance introduces PLPC-DB, a next-generation, non-cellular oncology immunotherapy platform now entering a global acquisition window. Unlike cell- or gene-based products, PLPC-DB is a lyophilized phospholipoproteic complex stable for more than 18 months at room temperature, eliminating cold-chain dependency and reducing infrastructure costs by over 60%. The platform is anchored in the Structured Immunophenotypic Traceability Platform (STIP), recently enhanced with a Network Access Module (NAM), ensuring auditable immune fingerprinting.

PLPC-DB Lyophilized Immunotherapy Vial and Packaging

PLPC-DB Lyophilized Immunotherapy Vial and Packaging
Concept rendering of PLPC-DB, a non-cellular oncology immunotherapy platform. Lyophilized formulation stable at room temperature for 18+ months.

Unlike cell- or gene-based products, PLPC-DB is a lyophilized phospholipoproteic complex stable for more than 18 months at room temperature. This eliminates cold-chain dependency and reduces infrastructure costs by over 60%, offering a scalable and sustainable option for oncology innovation.

Scientific and Regulatory Foundation

PLPC-DB is anchored in the Structured Immunophenotypic Traceability Platform (STIP), enhanced with a Network Access Module (NAM). This proprietary framework ensures interoperability and auditability of immune fingerprints, inter-batch consistency, and reproducibility across jurisdictions.

More than a decade of structured patient monitoring through the OncoVix program in Latin America supported the validation of STIP-NAM. By documenting outcomes in a standardized, transferable format, the system provides proportional validation without requiring sequential Phase I-III trials.

Independent regulatory consultancies have confirmed dossier maturity for FDA-facing discussions. This structure secures a valuation floor at USD 350M+, with upside >USD 600M following FDA filing (~2×) and >USD 1B under favorable Written Response Only outcomes (~3×).

Scientific Differentiation

PLPC-DB coordinates innate and adaptive immune responses, enhancing NK and CD8? effector activity and CD4? Th1 polarization. It improves antigen presentation (MHC I/II - CD8?/CD4?) and reduces inhibitory cytokines such as IL-10 and TGF-ß, reprogramming the tumor microenvironment.

These findings are supported by five PubMed-indexed Q1 publications and eleven Tier-1 oncology congress presentations. The program is directed by Dr. Ramón Gutiérrez-Sandoval M.D., oncopathologist and Chief Scientific Officer of OGRD Alliance.

Market Significance

The global oncology immunotherapy market exceeds USD 120B, with ~10% CAGR. PLPC-DB addresses cost and scalability barriers through:

  • Operational efficiency: shelf-stable, non-replicative formulation.

  • Access models: hospital-based and supervised at-home protocols.

  • Sustainability: aligned with UN Agenda 2030 and Vision 2030, reducing environmental and logistical burdens.

Unique Investment Profile

PLPC-DB is positioned as a de-risked pre-FDA asset, supported by regulatory validations, multiple publications, and a three-continent patent family with a 240-file trade-secret archive. It is structured for rapid valuation inflection once FDA milestones are achieved.

Global Licensing and Acquisition Window

PLPC-DB is currently in a preferential pre-sale phase open to qualified stakeholders. Following this stage, structured territorial licensing or regional alliances may be introduced.

Acquisition Options: OGRD Alliance confirms that both 80% and 100% ownership stakes are available for immediate transfer, subject to due diligence and binding agreements.

Links

  • Official site: www.PLPC-DB.com

  • PubMed Publications - OGRD Alliance: https://pubmed.ncbi.nlm.nih.gov/?term=ogrd+alliance

  • Official video overview: https://youtu.be/28D_c1yQziY

Media Contact: press@plpc-db.com

Disclaimer: PLPC-DB remains investigational. This release is for informational purposes only and refers exclusively to scientific findings, regulatory documentation, and investment opportunities. No therapeutic claims are being made.

Contact Information

Jose Leiner
Press Officer
press@plpc-db.com

.

SOURCE: OGRD Alliance



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/plpc-db-de-risked-oncology-immunotherapy-asset-with-global-licensing-window-and-stip-1067556

© 2025 ACCESS Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.